These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9663825)

  • 21. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
    Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S
    Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis.
    Murthy S; Cooper HS; Yoshitake H; Meyer C; Meyer CJ; Murthy NS
    Aliment Pharmacol Ther; 1999 Feb; 13(2):251-60. PubMed ID: 10102957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.
    Probert CS; Hearing SD; Schreiber S; Kühbacher T; Ghosh S; Arnott ID; Forbes A
    Gut; 2003 Jul; 52(7):998-1002. PubMed ID: 12801957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
    Tang R; Yang G; Zhang S; Wu C; Chen M
    Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.
    Casellas F; Papo M; Guarner F; Antolín M; Armengol JR; Malagelada JR
    Clin Sci (Lond); 1994 Oct; 87(4):453-8. PubMed ID: 7834999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
    Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
    Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
    van Dullemen HM; van Deventer SJ; Hommes DW; Bijl HA; Jansen J; Tytgat GN; Woody J
    Gastroenterology; 1995 Jul; 109(1):129-35. PubMed ID: 7797011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current therapeutic recommendations: infliximab for ulcerative colitis.
    Shen EH; Das KM
    J Clin Gastroenterol; 2004 Oct; 38(9):741-5. PubMed ID: 15365397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of TNFalpha in ulcerative colitis.
    Sands BE; Kaplan GG
    J Clin Pharmacol; 2007 Aug; 47(8):930-41. PubMed ID: 17567930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
    Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
    Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study.
    Sandborn WJ; Tremaine WJ; Leighton JA; Lawson GM; Zins BJ; Compton RF; Mays DC; Lipsky JJ; Batts KP; Offord KP; Hurt RD; Green J
    Aliment Pharmacol Ther; 1997 Aug; 11(4):663-71. PubMed ID: 9305473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease.
    Reinisch W; Heider KH; Oberhuber G; Dejaco C; Müllner M; Adolf GR; Gasché C
    Gut; 1998 Sep; 43(3):375-82. PubMed ID: 9863483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C; Wiebecke B; Loeschke K
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.